Stock SUD SUDA PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Suda Pharmaceuticals Ltd Australian S.E.

Equities

SUD

AU0000063661

Biotechnology & Medical Research

End-of-day quote Australian S.E.
Other stock markets
 		5-day change 1st Jan Change
- AUD -.--% Intraday chart for Suda Pharmaceuticals Ltd -.--% -.--%
Mar. 26 Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise MT
Mar. 20 Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 9.793 10.67 5.263 27.41 15.41 42.5
Enterprise Value (EV) 1 11.74 6.409 4.371 20.77 9.48 37.32
P/E ratio -1.79 x -0.94 x -0.53 x -3.74 x -1.47 x -3.49 x
Yield - - - - - -
Capitalization / Revenue 20.1 x 8.53 x 8.84 x 27.7 x 52.1 x 29.2 x
EV / Revenue 24.1 x 5.12 x 7.34 x 21 x 32 x 25.7 x
EV / EBITDA -3.48 x -2.88 x -0.95 x -5.44 x -1.27 x -4.37 x
EV / FCF -16.7 x -2 x -2.36 x -9.42 x -2.17 x -11.7 x
FCF Yield -5.99% -50.1% -42.4% -10.6% -46.1% -8.54%
Price to Book 0.85 x 0.76 x 1.27 x 3.05 x 2.02 x 11.2 x
Nbr of stocks (in thousands) 48,966 142,255 142,254 480,820 669,835 849,909
Reference price 2 0.2000 0.0750 0.0370 0.0570 0.0230 0.0500
Announcement Date 9/28/18 9/24/19 9/25/20 9/30/21 9/29/22 8/31/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.4867 1.251 0.5955 0.9897 0.2958 1.455
EBITDA 1 -3.377 -2.227 -4.609 -3.815 -7.461 -8.531
EBIT 1 -3.475 -2.349 -4.756 -3.956 -7.596 -8.632
Operating Margin -714.13% -187.8% -798.63% -399.66% -2,568.01% -593.4%
Earnings before Tax (EBT) 1 -6.778 -8.72 -10.59 -5.047 -8.621 -10.18
Net income 1 -5.459 -7.795 -9.936 -5.047 -8.621 -10.18
Net margin -1,121.75% -623.22% -1,668.33% -509.99% -2,914.23% -699.91%
EPS 2 -0.1117 -0.0800 -0.0698 -0.0153 -0.0157 -0.0143
Free Cash Flow 1 -0.7033 -3.211 -1.855 -2.205 -4.37 -3.186
FCF margin -144.51% -256.76% -311.51% -222.79% -1,477.36% -219.03%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/28/18 9/24/19 9/25/20 9/30/21 9/29/22 8/31/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 1.95 - - - - -
Net Cash position 1 - 4.26 0.89 6.64 5.93 5.18
Leverage (Debt/EBITDA) -0.5779 x - - - - -
Free Cash Flow 1 -0.7 -3.21 -1.86 -2.2 -4.37 -3.19
ROE (net income / shareholders' equity) -42.6% -61.3% -110% -77% -104% -179%
ROA (Net income/ Total Assets) -11.9% -8.93% -25.9% -28.4% -47.7% -73.5%
Assets 1 46.07 87.33 38.37 17.76 18.07 13.86
Book Value Per Share 2 0.2300 0.1000 0.0300 0.0200 0.0100 0
Cash Flow per Share 2 0 0.0300 0.0100 0.0100 0.0100 0.0100
Capex 1 0.07 0.31 0.14 0.17 0.04 0
Capex / Sales 14.04% 25% 23.69% 16.78% 11.84% 0.19%
Announcement Date 9/28/18 9/24/19 9/25/20 9/30/21 9/29/22 8/31/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALA Stock
  4. SUD Stock
  5. Financials Suda Pharmaceuticals Ltd